The FDA has issued a complete response letter to Japanese drug-maker Takeda Pharmaceutical regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone...
JDRF and Dexcom announced that they have formed a partnership whose goal is to accelerate the development of a novel wireless “smart transmitter” that would allow a continuous glucose monitor (CGM) system to communicate directly with an artificial pancreas...